Inflammation in Type 2 Myocardial Infarction

NYU Langone Health

Overview

Type 2 myocardial infarction (MI) is defined as myocardial necrosis that results from an imbalance of myocardial oxygen supply and demand. Although type 2 MI is highly prevalent in patients with critical illness and strongly associated with mortality, the pathophysiology remains poorly understood. Inflammation is central to the development of atherosclerosis, plaque rupture, and other subtypes of MI, but the role of inflammation in type 2 MI and myocardial necrosis has not been defined. The investigators aim to to delineate the mechanistic role of inflammation in myocardial necrosis and type 2 MI complicating critical medical illness.

Study Type

OBSERVATIONAL

Conditions

Myocardial Infarction Inflammation Critical Illness

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥21 years of age * admitted to the Medical Intensive or Coronary Care Units * sepsis or respiratory failure * clinically indicated troponin measurement within 24 hours of ICU admission Exclusion Criteria: * unstable angina or Type 1 MI * percutaneous or surgical coronary revascularization within 7 days * heart failure exacerbation * primary valvular disorder * aortic dissection * infiltrative heart disease or hypertrophic cardiomyopathy * myocarditis * pulmonary embolism * electrocardiogram with \>1mm ST segment elevation in two consecutive leads * serum cardiac troponin \>99th percentile URL but no clear rise or fall pattern * history of chronic inflammatory disease * use of therapeutic-dose anticoagulants / antiplatelet agents other than aspirin * pregnant or incarcerated * enrolled in a competing study

Locations (1)

Bellevue Hospital Center

New York, New York, United States

Outcomes

Primary Outcomes

Leukocyte-platelet aggregates

Time frame: Day 1

Secondary Outcomes

Leukocyte-platelet aggregates

Participants will be followed for the duration of hospital stay, an expected average of 10 days.

Time frame: Day 10

Monocyte-platelet aggregates

Time frame: Day 1

Monocyte-platelet aggregates

Participants will be followed for the duration of hospital stay, an expected average of 10 days.

Time frame: Day 10

Neutrophil-platelet aggregates

Time frame: Day 1

Neutrophil-platelet aggregates

Participants will be followed for the duration of hospital stay, an expected average of 10 days.

Time frame: Day 10

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.